Published in Psychooncology on February 28, 2013
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. J Clin Oncol (2015) 0.93
Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics (2013) 0.91
Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care (2016) 0.81
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Genet Med (2015) 0.81
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. J Natl Compr Canc Netw (2015) 0.78
Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. Breast Cancer Res Treat (2016) 0.75
Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists. Curr Oncol (2017) 0.75
The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. Breast Cancer Res Treat (2016) 0.75
Three approaches to qualitative content analysis. Qual Health Res (2005) 56.35
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Shared decision making--pinnacle of patient-centered care. N Engl J Med (2012) 8.74
Sample size in qualitative research. Res Nurs Health (1995) 7.10
Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med (2004) 5.18
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Patient preferences for colorectal cancer screening. J Fam Pract (1997) 4.55
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol (2008) 3.89
Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making (2007) 3.74
Can women with early-stage breast cancer make an informed decision for mastectomy? J Clin Oncol (2008) 3.37
Clinical implications of numeracy: theory and practice. Ann Behav Med (2008) 2.69
Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst (2011) 2.61
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Latina patient perspectives about informed treatment decision making for breast cancer. Patient Educ Couns (2008) 2.17
Varieties of uncertainty in health care: a conceptual taxonomy. Med Decis Making (2011) 2.11
Physician decision making and cardiac risk: effects of knowledge, risk perception, risk tolerance, and fuzzy processing. J Exp Psychol Appl (2006) 2.03
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer (2007) 2.03
Evidence Based Medicine and Shared Decision Making: the challenge of getting both evidence and preferences into health care. Patient Educ Couns (2008) 1.94
An informed decision? Breast cancer patients and their knowledge about treatment. Patient Educ Couns (2006) 1.87
US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A (2003) 1.77
Genomics education for health care professionals in the 21st century. JAMA (2011) 1.69
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast (2009) 1.62
Telling "everything" but not "too much": the surgeon's dilemma in consultations about breast cancer. World J Surg (2011) 1.52
"Could this be something serious?" Reassurance, uncertainty, and empathy in response to patients' expressions of worry. J Gen Intern Med (2007) 1.51
An approach to measuring the quality of breast cancer decisions. Patient Educ Couns (2006) 1.50
Impact of physician-patient discussions on patient satisfaction. Med Care (2008) 1.44
Debating clinical utility. Public Health Genomics (2010) 1.41
Shared decision making in oncology practice: what do oncologists need to know? Oncologist (2012) 1.39
Impact of format and content of visual display of data on comprehension, choice and preference: a systematic review. Int J Qual Health Care (2011) 1.24
Molecular profiling of breast cancer: clinical implications. Br J Cancer (2004) 1.19
Clinical gist and medical education: connecting the dots. JAMA (2009) 1.18
Health decision making: lynchpin of evidence-based practice. Med Decis Making (2008) 1.14
Using visual aids to improve communication of risks about health: a review. ScientificWorldJournal (2012) 1.12
From "reducing" to "coping with" uncertainty: reconceptualizing the central challenge in breast self-exams. Soc Sci Med (2000) 1.03
Uncertainty in breast, prostate, and colorectal cancer: implications for supportive care. J Nurs Scholarsh (2008) 1.01
Communicating risk. BMJ (2012) 1.00
Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? Br J Cancer (2005) 0.99
Uncertainty, responsibility, and the evolution of the physician/patient relationship. J Med Ethics (2006) 0.99
Improving communication of breast cancer recurrence risk. Breast Cancer Res Treat (2011) 0.98
Information sharing and case conference among the multidisciplinary team improve patients' perceptions of care. Open Nurs J (2011) 0.95
Shared decision making in oncology: assessing oncologist behaviour in consultations in which adjuvant therapy is considered after primary surgical treatment. Health Expect (2010) 0.93
BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat (2010) 0.92
Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A (2005) 0.91
The surgeon-patient interaction in older women with breast cancer: what are the determinants of a helpful discussion? Ann Surg Oncol (2006) 0.90
Multidisciplinary care for patients with breast cancer. Surg Clin North Am (2009) 0.85
Personalized participatory medicine: sharing knowledge and uncertainty. Genome Med (2011) 0.81
Coordination of care in breast cancer survivors: an overview. J Support Oncol (2011) 0.76
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Parents' perspectives on physician-parent communication near the time of a child's death in the pediatric intensive care unit. Pediatr Crit Care Med (2008) 3.00
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol (2009) 2.52
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Hot flushes. Lancet (2002) 2.28
Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology (2007) 2.18
Parents' perspectives regarding a physician-parent conference after their child's death in the pediatric intensive care unit. J Pediatr (2007) 2.18
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol (2002) 2.13
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst (2011) 2.09
All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol (2002) 1.69
Association between nonverbal communication during clinical interactions and outcomes: a systematic review and meta-analysis. Patient Educ Couns (2011) 1.69
Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol (2004) 1.66
The Cancer Genetics Network: recruitment results and pilot studies. Community Genet (2003) 1.61
Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol (2002) 1.58
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol (2005) 1.58
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol (2008) 1.57
Patient-provider communication differs for black compared to white HIV-infected patients. AIDS Behav (2011) 1.56
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat (2006) 1.51
Feasibility and perceived benefits of a framework for physician-parent follow-up meetings after a child's death in the PICU. Crit Care Med (2014) 1.49
Intention to undergo colonoscopy screening among relatives of colorectal cancer cases: a theory-based model. Ann Behav Med (2014) 1.49
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer Epidemiol Biomarkers Prev (2006) 1.48
Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47
Breaking bad news in the breast imaging setting. Acad Radiol (2009) 1.47
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res (2003) 1.43
Differences in patient-provider communication for Hispanic compared to non-Hispanic white patients in HIV care. J Gen Intern Med (2010) 1.43
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol (2003) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life. Psychooncology (2008) 1.37
Communicating professional identity in medical socialization: considering the ideological discourse of morning report. Qual Health Res (2004) 1.35
Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test (2008) 1.31
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
Development and evaluation of a culturally tailored educational video: changing breast cancer-related behaviors in Chinese women. Health Educ Behav (2007) 1.28
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol (2010) 1.27
A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev (2005) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
The influence of culture and cancer worry on colon cancer screening among older Chinese-American women. Ethn Dis (2006) 1.25
Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer (2004) 1.25
NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies. Ann Emerg Med (2010) 1.24
Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev (2005) 1.24
Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol (2006) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev (2009) 1.22
The development of a web- and a print-based decision aid for prostate cancer screening. BMC Med Inform Decis Mak (2010) 1.21
Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C Semin Med Genet (2006) 1.21
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat (2006) 1.20
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20
Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther (2007) 1.20
Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.19